Danish Drama: Genmab Drops $8B on Cancer Cure Hope Seller
In a move that screams 'we have billionaire money to burn,' Danish biotech bigwig Genmab announced it plans to acquire Merus, the brainiac behind a shiny new head and neck cancer drug, for around $8 billion. That's $8 billion, or roughly the cost of buying every Danish pastry in Copenhagen twice over. This deal lands Genmab firmly in Life Sciences prime, scheming to turn biology into cold, hard kroner. With cancer therapy innovation like this on the line, letâs hope Merus's drug fights neck and head tumors better than Genmab fought that price tag.
Share the Story
(1 of 3)Genmab just dropped $8 billion on Merus like itâs Black Friday for biotech, apparently 'saving cancer patients' is easier when you have a billionaire bankroll appearing out of nowhere.
Buying a head and neck cancer drug developer for $8 billion is peak pharmaceutical flexâGenmabâs basically saying, 'Weâll fix your cells, but first, show us the money.'
Genmab buying Merus is like paying $8 billion for a Tesla upgradeâyouâre still hoping it doesnât break down, but hey, it looks promising!
Source: Statnews | Published: 9/29/2025 | Author: Andrew Joseph
More Articles in Business
Army Launches 9-1-1 Hotline Because Soldiers Really Love Calling IT
Microsoft Finally Lets Windows 11 Fans Stop Pretending to Use ViVeTool
Epstein Survivors Declare 'Done' While Melania Passes the Buck Faster Than a Baton
Entrepreneurs Swear By Hulkens, Because Carrying Packages in Style is a Hustle
Walmart Cuts H-1B Visa Applications by Half, Still Outselling Visa Restrictions
Bobbi Brown Got Fired, Didn't Cry, Just Launched Another Empire
Texas Company Turns Man Camps Into Mansion Camps for AI Construction Bros
Volkswagen Kills Its Own EV Baby, Prefers Gas-Guzzling Siblings
